Read Our

Equisights Research (“Equisights”) is a distinguished independent sell-side research firm that excels in delivering in-depth, objective analysis and strategic insights. Our research efforts are primarily centered on the U.S. markets, with a strong sectoral emphasis on Technology, Media, and Telecommunications (TMT), healthcare, consumer cyclicals & non-cyclicals, industrials, energy, and select financials. Equisights serves to several notable buy-side funds, RIAs, family offices, and over 1,000 institutional relationships, who take positions across our coverage universe and manage portfolios ranging from $100 million to $1 billion in assets.

Our comprehensive research framework involves an in-depth analysis of each company’s growth potential, financial health, management quality, industry position, risk factors, and valuation. Our recommendations and ratings process is based on gathering and interpreting data, drawing conclusions, and evaluating these factors to determine final ratings based on intrinsic value, expected growth, and risks. Equisights maintains its independence by not participating in public offerings, advising on mergers and acquisitions, brokering trades, making markets in stocks, or managing money.

RESEARCH FEED : OUR PERSPECTIVE

18 Sep, 2024

Targa Resources (TRGP): Turning Down Takeovers? A Bull’s Perspective on Their Focused Organic Expansion and Market Leverage!

According to Bloomberg, Targa Resources Corp. recently rejected informal takeover interest from larger competitor Williams Cos., signaling ongoing consolidation appetite in the pipeline sector. Targa viewed Williams’ approach as undervaluing its current market capitalization, reflecting the company’s strategic resistance to transactions perceived as misaligned with its valuation trajectory. Wi... Read More
18 Sep, 2024

Target Corporation (TGT): Traffic and Tech “Drive Up” Gains, But Does Discretionary Weakness Raise Longer-Term Questions!

Target’s Q2 fiscal 2024 results showcased solid top-line growth and operating margin improvement, with comparable store sales rising by 2% and operating margins expanding by 160 basis points to 6.4%. This performance drove a significant stock price increase. However, the results warrant a deeper analysis. While positive same-store sales reflect Target’s ability to recover from a challenging pe... Read More
18 Sep, 2024

Atlassian Corporation (TEAM): Balancing Short-Term Slowdown with Long-Term 2027 Targets !

Atlassian reported strong Q4 results, with revenue growing 20% year-over-year to $1.132 billion, slightly exceeding guidance. Subscription revenue increased by 34% year-over-year to $1.069 billion, due to lower seat counts and late deal closures. Cloud revenue also grew 31% to $738 million, driven by migrations and upsell. Data center revenue grew 41%, matching guidance, while non-GAAP operating m... Read More
18 Sep, 2024

STERIS Plc (STE): Riding the Crest of Procedural Growth—Balancing Headwinds with Recurring Revenue and Margin Expansion !-

STERIS CEO Daniel Carestio emphasized strong procedural volume growth in the U.S., with high single-digit rebounds in the Rust Belt and robust demand across Sun Belt states. Europe lags behind by 6-9 months, but recovery signals are emerging. We believe STERIS is capitalizing on the shift from acute care hospitals to ASCs, driving demand for its sterilization equipment and consumables, further sol... Read More
18 Sep, 2024

Altria (MO): Battling Illicit Market Pressures—Evaluating Key Cost & Profit Drivers Amid Challenging Market Dynamics

Altria's second-quarter 2024 results reveal a business navigating both pressures and opportunities. The company faces a continued decrease in cigarette volumes, exacerbated by macroeconomic challenges and the rise of illicit e-vapor products, which now account for more than 60% of the market. Nicotine pouches and alternative tobacco products are gaining traction, further intensifying competition. ... Read More
18 Sep, 2024

Lowe’s Companies, Inc (LOW): Flywheel Effect?—Pro-Growth Momentum and AI Investments Setting the Stage!

Lowe’s Q2 2024 results reflected the effects of weakened consumer spending, with same-store sales down 5.1% and a 5.5% decline in total revenue. However, professional sales rose in the mid-single digits, and online sales grew 2.9%, highlighting pockets of resilience. However, Pro sales and online growth provided resilience, showcasing the strength of Lowe’s Total Home strategy and omnichannel ... Read More
18 Sep, 2024

Illinois Tool Works: Weathering the Storm—Margin Strength Holds, but Growth Still in the Balance- What Lies Ahead ?

Illinois Tool Works (ITW) faces headwinds tied to softening demand in short-cycle and CapEx-sensitive segments, particularly Welding, Test & Measurement, and Construction Products. Additionally, a 2% decline in automotive builds, compounded by foreign currency impacts and higher tax rates, has pressured EPS. Weakness in semiconductor and electronics markets has further weighed on results. Howe... Read More
18 Sep, 2024

Illinois Tool Works: Weathering the Storm—Margin Strength Holds, but Growth Still in the Balance- What Lies Ahead ?

Illinois Tool Works (ITW) faces headwinds tied to softening demand in short-cycle and CapEx-sensitive segments, particularly Welding, Test & Measurement, and Construction Products. Additionally, a 2% decline in automotive builds, compounded by foreign currency impacts and higher tax rates, has pressured EPS. Weakness in semiconductor and electronics markets has further weighed on results. Howe... Read More
18 Sep, 2024

The Hershey Company (HSY): Leveraging Seasonal Demand with Ramped Up Innovation & Continued Investments

Hershey’s Q2 2024 results reflected mixed dynamics with headwinds. Revenue of $2.07B missed expectations by $246M, down 16.7% YoY and 36.2% sequentially, driven by an 8-9% impact from lower retail inventory levels and Halloween timing shifts. Net price realization improved 6-7% through targeted pricing actions, but elevated cocoa costs continued to pressure gross margins despite some temporary r... Read More
18 Sep, 2024

EW: What Makes Edwards Lifesciences a Hot Acquisition Target—And What’s It Really Worth

Edwards Lifesciences’ Q2 2024 performance delivered mixed results, with revenue up 6.67% YoY to $1.63 billion, but missing expectations by $20.9 million. The company’s standout TMTT segment saw a 75% surge in sales, driven by strong adoption of the PASCAL and EVOQUE systems, positioning Edwards as a leader in the rapidly expanding mitral and tricuspid valve markets. However, the TAVR segment, ... Read More
Earnings
Market Pulse
Deals
Scroll to Top